164 related articles for article (PubMed ID: 24978332)
1. Pretherapeutic dosimetry in patients affected by metastatic thyroid cancer using 124I PET/CT sequential scans for 131I treatment planning.
Pettinato C; Spezi E; Nanni C; Grassetto G; Monari F; Allegri V; Civollani S; Cima S; Zagni P; Mazzarotto R; Colletti PM; Rubello D; Fanti S
Clin Nucl Med; 2014 Aug; 39(8):e367-74. PubMed ID: 24978332
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of 124I PET/CT imaging to predict absorbed doses in patients affected by metastatic thyroid cancer and treated with 131I.
Pettinato C; Monari F; Nanni C; Allegri V; Marcatili S; Civollani S; Cima S; Spezi E; Mazzarotto R; Fanti S
Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):509-14. PubMed ID: 23358403
[TBL] [Abstract][Full Text] [Related]
3. Recombinant Human Thyroid-Stimulating Hormone Versus Thyroid Hormone Withdrawal in
Plyku D; Hobbs RF; Huang K; Atkins F; Garcia C; Sgouros G; Van Nostrand D
J Nucl Med; 2017 Jul; 58(7):1146-1154. PubMed ID: 28104741
[TBL] [Abstract][Full Text] [Related]
4. Dose-Response Relationship in Differentiated Thyroid Cancer Patients Undergoing Radioiodine Treatment Assessed by Means of 124I PET/CT.
Wierts R; Brans B; Havekes B; Kemerink GJ; Halders SG; Schaper NN; Backes WH; Mottaghy FM; Jentzen W
J Nucl Med; 2016 Jul; 57(7):1027-32. PubMed ID: 26917706
[TBL] [Abstract][Full Text] [Related]
5. High Level of Agreement Between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases.
Ruhlmann M; Jentzen W; Ruhlmann V; Pettinato C; Rossi G; Binse I; Bockisch A; Rosenbaum-Krumme S
J Nucl Med; 2016 Sep; 57(9):1339-42. PubMed ID: 27151981
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer.
Capoccetti F; Criscuoli B; Rossi G; Ferretti F; Manni C; Brianzoni E
Q J Nucl Med Mol Imaging; 2009 Oct; 53(5):536-45. PubMed ID: 19910907
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.
Eschmann SM; Reischl G; Bilger K; Kupferschläger J; Thelen MH; Dohmen BM; Besenfelder H; Bares R
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):760-7. PubMed ID: 12029549
[TBL] [Abstract][Full Text] [Related]
8. Assessment of lesion response in the initial radioiodine treatment of differentiated thyroid cancer using 124I PET imaging.
Jentzen W; Hoppenbrouwers J; van Leeuwen P; van der Velden D; van de Kolk R; Poeppel TD; Nagarajah J; Brandau W; Bockisch A; Rosenbaum-Krumme S
J Nucl Med; 2014 Nov; 55(11):1759-65. PubMed ID: 25332440
[TBL] [Abstract][Full Text] [Related]
9. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer.
Freudenberg LS; Jentzen W; Marlowe RJ; Koska WW; Luster M; Bockisch A
Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):690-3. PubMed ID: 18058605
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
Lee JW; Lee SM; Lee DH; Kim YJ
J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
[TBL] [Abstract][Full Text] [Related]
11. 124I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact.
Freudenberg LS; Jentzen W; Görges R; Petrich T; Marlowe RJ; Knust J; Bockisch A
Nuklearmedizin; 2007; 46(4):121-8. PubMed ID: 17690789
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer.
de Keizer B; Hoekstra A; Konijnenberg MW; de Vos F; Lambert B; van Rijk PP; Lips CJ; de Klerk JM
J Nucl Med; 2004 Sep; 45(9):1549-54. PubMed ID: 15347723
[TBL] [Abstract][Full Text] [Related]
13. Optimal Time for 124I PET/CT Imaging in Metastatic Differentiated Thyroid Cancer.
Wu D; Plyku D; Kulkarni K; Garcia C; Atkins F; Tefera E; Burman KD; Wartofsky L; Van Nostrand D
Clin Nucl Med; 2021 Apr; 46(4):283-288. PubMed ID: 33492859
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck.
Nagarajah J; Jentzen W; Hartung V; Rosenbaum-Krumme S; Mikat C; Heusner TA; Antoch G; Bockisch A; Stahl A
Eur J Nucl Med Mol Imaging; 2011 Oct; 38(10):1862-8. PubMed ID: 21739331
[TBL] [Abstract][Full Text] [Related]
15. Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma.
Maruoka Y; Abe K; Baba S; Isoda T; Sawamoto H; Tanabe Y; Sasaki M; Honda H
Radiology; 2012 Dec; 265(3):902-9. PubMed ID: 23012466
[TBL] [Abstract][Full Text] [Related]
16. 124I PET/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET).
Kist JW; de Keizer B; van der Vlies M; Brouwers AH; Huysmans DA; van der Zant FM; Hermsen R; Stokkel MP; Hoekstra OS; Vogel WV; ;
J Nucl Med; 2016 May; 57(5):701-7. PubMed ID: 26609180
[TBL] [Abstract][Full Text] [Related]
17. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.
Jentzen W; Balschuweit D; Schmitz J; Freudenberg L; Eising E; Hilbel T; Bockisch A; Stahl A
Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2298-306. PubMed ID: 20625723
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
[TBL] [Abstract][Full Text] [Related]
19. Acquisition settings for PET of 124I administered simultaneously with therapeutic amounts of 131I.
Lubberink M; van Schie A; de Jong HW; van Dongen GA; Teule GJ
J Nucl Med; 2006 Aug; 47(8):1375-81. PubMed ID: 16883019
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
